IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (1214)	8/18/1997 11:18:00 PM
From: scaram(o)uche	of 1762

Nice results. Is it known yet if the remissions are as durable as those induced by CHOP? An Idec release (12/9/96) doesn't talk about degree of tumor burden. Complete remissions were 22/35 compared to the 7/17. I haven't seen further data, and I don't know that one wouldn't get 22/35 with CHOP alone. In the context of Bexxar use for first-line (thanks!, you just put me much further up on the learning curve), it should be pointed out that other anti-CD20s have also been reported to suppress the expression of bcl-2. So, there's no reason to assume that B1 would not. Then, the only hinge that Idec would have would be the "bcl-2 plays a role in resistance to CHOP" hinge. If the apoptosis story is relevant, it wouldn't be unique to Idec. Again, I have no idea if there's data to support this. If there's anything to the bcl-2 concept, it'll be facsinating, irrespective of whether or not it's related to chemo. I have a vague memory that ImmunoGen reported bcl-2 suppression, in a mouse model, with their anti-CD20. Cheers! Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next